Q-omics provides the consensus-scored PRSS46P profile across patient tissues and cancer cell-line models. PRSS46P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PRSS46P is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, PRSS46P RNA expression shows 15,162 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, LUAD, and UVM as cancer lineages where PRSS46P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS46P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS46P survival associations across molecular data types. PRSS46P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS46P RNA expression–survival associations across cancer types. High PRSS46P expression shows unfavorable associations in COAD, ACC, DLBC and LUSC, but favorable associations in UCS and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for PRSS46P RNA expression.
This table summarizes PRSS46P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRSS46P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS46P shows lower tumor expression in BRCA, PRAD and BLCA and higher tumor expression in LUAD, UCEC and CHOL. The LUAD box plot shows higher PRSS46P RNA expression in tumor versus normal tissue (log2 FC = +0.476, t-test p < 0.001).
This table shows molecular features associated with PRSS46P in patient tissues and cancer cell lines. In patient samples, PRSS46P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
